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Summary 
 
Cystic fibrosis (CF) is an autosomal recessive disease 
caused by mutation of the cystic fibrosis 
transmembrane conductance regulator (CFTR).  CFTR is 
a protein forming chloride channels in the membrane of 
epithelial cells.  It consists of two transmembrane 
domains (TMD), two nucleotide binding domains (NBD), 
and an R domain.  The channel is first activated by the 
phosphorylation of its R domain. ATP then binds to 
CFTR’s NBDs for the channel to conduct Cl
-
 out of the 
cell.  Mutations in CFTR can cause misfolding and 
prevent adequate transportation of Cl
-
.  The most 
common cause of the disease is the deletion of 
phenylalanine 508 of CFTR. When F508 reaches the 
ER, it is recognized as irreparable and thus targeted for 
degradation, which causes the symptoms of CF. The 
third most common mutation, G551D, does not function 
properly at the membrane. Molecular chaperones such 
as Hdj-2/Hsc70, Hsp90, and HspBP1 may rescue CFTR 
misfolding. This has therapeutic value because once 
F508 is sent to the membrane, it can function normally. 
There are many treatments for CF, including airway 
clearing techniques, antibiotics, and lung 
transplantation. Recent research has suggested that 
oligonucleotide insertion, curcumin treatment, and 
digotoxin treatment can reverse the F508 phenotype. 
 
Introduction 
 
Cystic Fibrosis (CF) is a disease marked by an ineffective 
chloride channel that afflicts thousands of individuals every 
year, yet there is still no known cure.  It was first diagnosed 
in the 1700s by kissing a child on the forehead and if their 
sweat tasted salty, the parents knew their child had the 
disease (Littlewood, 2002).  Currently, there are many more 
definitive ways of diagnosing this fatal disease.  In 1938, 
Dorothy Anderson described the symptoms of a child with 
cystic fibrosis in detail, such that they could be applied in a 
clinical setting.  By examining family inheritance, in 1946, 
Anderson discovered that cystic fibrosis was a recessive 
genetic disease.  In 1953, it was revealed that children with 
cystic fibrosis had increased sweat electrolytes and 
therefore, sweat tests became an accurate means for 
diagnosis.  Neonatal screening began in the 1970s, allowing 
for earlier diagnosis of this disease.  In 1988, the first and 
most common mutation associated with cystic fibrosis, 
F508, was found on chromosome 7 (Littlewood, 2002).   
Cystic fibrosis is an autosomal recessive disease 
caused by the mutation of the CFTR gene.   In 1985, the 
CFTR gene was located at 7q21-34, on the long arm of 
chromosome 7, which was soon followed by the 
identification of the gene sequence (Welsh, et al., 2001).  
The CFTR gene codes for a protein which contains 1480 
amino acids and has been named the cystic fibrosis 
transmembrane conductance regulator, also known as 
________________________________________________  
 
*This author wrote the paper for Biology 221:  Cell and Molecular Biology taught 
by Dr. Shubhik DebBurman. 
CFTR (Southern, 1997).  A mutation in CFTR often leads to 
CF. CFTR is a chloride channel expressed on the surface of 
epithelial cells in the intestine, respiratory system, pancreas, 
and sweat glands. Currently, there are over 1000 mutations 
comprising four classes that result in CF; however, one 
mutation, the deletion of phenylalanine at position 508, 
accounts for over 70% of CF patients. The other mutations 
are very rare, and only 4 others have frequencies above 1% 
(Littlewood, 2002).  
 There are over 1,000 new cases of cystic fibrosis 
diagnosed each year, and about 90% are diagnosed before 
the child is 3-years-old.  Cystic fibrosis is most common 
among people of European background, with carrier 
numbers of 1 in 25.  Mortality rates have been dramatically 
altered since the 1960s.  In 1969, the mean life expectancy 
was 14 years.  In 2005, however, it was 36.8 years 
(McCutchen, 2007). 
 CF is characterized by thick mucus secretions in 
the pancreas, lungs, and reproductive organs. These thick 
mucus secretions block the airways and cause chronic 
bacterial infection and degeneration of the lung tissue.  
Patient death is often due to recurrent infections. Other 
symptoms of CF are the destruction of the pancreas and 
sterility in males (Quekett, 2007). 
A common biological model for CF is a transgenic 
mice model (Clarke, et al., 1992).  Recently, efforts have 
been made to map the entire genetic structure of the most 
common cause of CF infection: the Pseudomonas 
aeruginosa bacterium.  This way researchers can identify 
specific genes that cause the infection and turn off the target 
genes when needed (CFF.org, 2007) 
CF does not have a cure; the only available 
therapies currently address the symptoms of the disease. 
Patients that suffer from severe lung disease caused by CF 
have the option of lung transplantation (CFF.org, 2007). 
Another treatment option for CF is the use of airway-clearing 
techniques to loosen the thick mucus in the lungs, making it 
easier to expel by coughing. Antibiotics used to treat CF are 
administered orally, intravenously, or inhaled. Inhaled drugs 
are commonly used after airway-clearing techniques and 
have the unique ability to reach the airways quickly and 
easily. Gene therapy is not a currently available treatment for 
CF, but offers considerable promise if a proper vector can be 
found. These treatments present patients only temporary 
relief from their symptoms, and there is ongoing research to 
find a cure by specifically targeting mutations such as 
F508. 
Cystic fibrosis is a very well studied disease; 
however, there is still much to be learned.  Over the past few 
years, tremendous advances have been made in this field.  
To understand the cellular impact of CF, we must first 
recognize how CFTR functions normally.  Mutations causing 
CFTR to misfold and function abnormally, or not at all, must 
also be identified.  To correct the adverse effects of these 
mutations, regulation of chaperones is a useful strategy.  
Addressing all of these factors lead to improvements in 
therapy, though there is still no cure for the disease.  
 
Normal Function of CFTR 
 
The key to discovering how mutations can affect CFTR is to 
first identify the channel’s normal functioning.  CFTR is a 
protein found in the membrane of epithelial cells that acts as 
a chloride channel, moving negatively charged chloride ions 
out of the cell (Sheppard and Welsh, 1999).  The transport of 
chloride is  essential in maintaining  constant cell volume.  In  
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Figure 1. CFTR chloride channel structure. (Journal of NIH Research http://history.nih.gov/exhibits/genetics/10b-sm.gif). 
 
a process called RVD response, the chloride channels are 
activated allowing chloride to flow passively through the 
channels with water to restore homeostasis.  CFTR is found 
in cells comprising many organs including the lung, 
pancreas, liver, or any other systems that require fluid 
mucus for their function.  The water that is transported along 
with the negatively charged ions hydrates the cellular 
secretions in the aforementioned organs, aiding in fluidity 
(Anderson, 1992).  In normal lungs the stabilization of NaCl 
concentration is aided by the passive transport of water into 
and out of the cells, producing a low salt content in the 
surface liquid coating airway epithelial cells (Dorin, 2004). 
This low salt environment facilitates the growth of naturally 
occurring antimicrobial peptides that fight off bacterial 
infections. 
Consisting of two transmembrane domains (TMD1 
and TMD2) along with two nucleotide binding domains 
(NBD1 and NBD2) (Riordan et al., 1989), CFTR is a member 
of the ABC transporter family due to its utilization of ATP 
hydrolysis in function (see Fig 1).    
CFTR is activated when ATP binds to both its 
nucleotide binding domains causing NBD1-NBD2 
dimerization (Vergani, et al., 2005).  However, before ATP 
binds, protein kinase A (PKA) must first phosphorylate the R 
Domain of the protein, bridging the two homologous halves 
(the TMDs), and giving the protein configuration as follows: 
TMD1-NBD1-R-TMD2-NBD2 (Gadsby, et al., 2006).  
Negatively charged ions, such as chloride, are thought to 
accumulate near the positively charged regions of the pore 
until phosphorylation and ATP binding activates its opening, 
allowing the ions to flow through, down their concentration 
gradient. 
Upon the intramolecular dimer interaction initiated 
by ATP binding to NBD1 followed by ATP binding to NBD2, 
a signal is transmitted through cytoplasmic linking domains 
to open the gate in the transmembrane domain.  The 
activated channel is characterized by two open conductance 
states: O1 and O2 (Gunderson and Kopito, 1995).   The O2 
confirmation results in a 15% larger opening than O1, but the 
open CFTR confirmation only exists in this state 20% of the 
time.   
The channel closes in two different ways, ATP 
dissociation or ATP hydrolysis, both of which result in a 
decrease of hydrogen bonding between the NBD domains 
(Ramjeesingh, et al., 2003).  Both cause a destabilization of 
the NBD dimer and consequently a lack of signal 
transmission through the cytoplasmic linking domains, 
causing the channel to close (Gadsby, et al., 2006). 
The activity of the channel is characterized by the 
following directionality: CO1O2C.  Because the 
pathway is strictly directional, this gives further evidence that 
an outside source of energy (i.e. ATP) is needed to drive the 
gating asymmetry (Gunderson and Kopito, 1995). 
Mutations in CFTR directly affect chloride 
conductance across the cell membrane, and without efficient 
anion flow, water movement slows and dehydrated mucus 
clogs and accumulates in organ ducts, fostering bacterial 
growth (Gadsby, et al., 2006).  In addition to the decreased 
fluidity and increase in bacterial growth, because 
antimicrobial activity requires a low salt concentration and 
because CF surface fluid has a high NaCl concentration, 
Cystic Fibrosis epithelia fail to kill the thriving bacteria 
(Smith, at al., 1996).  Failure of CFTR to function properly is 
often the effect of a number of mutations. 
 
Class II mutation F508: the Most Common Mutation in 
CF 
 
There are four class mutations associated with CF, the most 
common form being the codon deletion of pheylalanine 
residue at position 508 from the NBD1 of the CFTR 
(Southern, 1997). The mutation of F508 is a class II 
mutation and affects the maturation of CFTR by inducing 
misfolding (Welsh, 2001). When the mutated CFTR protein 
reaches the ER, the quality-control mechanism of its cellular 
component recognizes that the protein is folded incorrectly 
and marks the defective protein for degradation. As a result, 
F508 does not reach the cell membrane (Cui, 2006). Unlike 
CFTR, once wild type (WT) CFTR is synthesized it is 
transported to the ER and proceeds to the plasma 
membrane through ER export. Interestingly, the F508 
mutation does not alter the chloride channel ability of CFTR 
but rather corrupts the normal intracellular processing of the 
protein (Southern, 1997). Recently, scientists have 
concentrated on defining the class II mutation F508 and, in 
the process, are discovering its functions, leading to better 
understanding of this fatal defect.  
 
Protein Kinase CK2, CFTR, F508: F508 Deletion Disrupts 
a Kinase-Binding Site 
 CFTR is part of a macromolecular complex in the apical 
membrane of epithelia comprising a number of protein 
kinases. The means by which F508 CFTR alters the 
function of unrelated proteins is currently unknown. Through 
immunoprecipitation and Western blotting, Treharne, et al. 
(2007) examined the relationship between the protein kinase 
CK2 and F508.  They found that CK2 associates with WT-
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CFTR but not F508 CFTR. Thus, CK2 appears to aid in the 
regulation of CFTR activity.  
 Knowing that F508 is dependent on CK2-CFTR 
interaction, Treharne, et al. (2007) investigated whether the 
deletion of F508 disrupts binding of signaling molecules.  It 
was confirmed that CK2 phosphorylates WT but not F508. 
To test whether Ser-511 is phosphorylated by CK2 in WT-
CFTR, Ser-511 was mutated in recombinant NBD1 
(Treharne, et al., 2007). The results indicated that CK2 failed 
to phosphorylate the S-511 mutant (Treharne, et al., 2007). 
Thus, neither F508-NBD1 nor mutated Ser-511-NBD1 
interacts with CK2.  
 It remains unclear how the loss of F508 leads to 
defective channel gating. Treharne, et al. (2007) examined 
the role of the Ser-511 mutation in CFTR function and found 
that both F508 and F508-Ser-511 disrupt CFTR channel 
gating—Ser-511 more so than F508. From this data, it may 
be interpreted that Ser-511 may be involved in trafficking 
(Treharne, et al., 2007). 
 CK2 can use either ATP or GTP as a phosphate 
donor for kinase activity, making it an attractive candidate for 
future research of CF. F508-CFTR interactions have shown 
that explanations for the multi-system nature of CF may 
reside in differences between proteins bound to WT and 
F508 CFTR. These findings suggest that the normal 
function of CFTR is to either maintain the CK2 content of the 
apical membrane or to provide a F508-dependent anchoring 
protein for CK2 (Treharne, et al., 2007). CK2 regulated 
F508 CFTR dependently, and Ser-511 is a critical residue 
in CK2-dependent gating of CFTR. Thus, F508 is critical for 
CK2 to bind CFTR and phosphorylate NBD1 at Ser-511. 
 
The Role of CFTR Phenylalanine 508 Side Chain Ion 
Channel Gating 
CFTR functions as a chloride channel and the deletion of 
Phe508 in the NBD1 impairs both maturation and function of 
the protein.  Although F508 is retained in the ER, it is still 
able to function as an ion channel (Welsh, 2001). Through 
the substitution of Phe508 by several other residues rather 
than being deleted, Cui, et al. (2006) found that CFTR was 
able to mature and be transported to the cell surface. Cui, et 
al. (2006) investigated this proposition further by researching 
the role of the Phe508 side chain in the CFTR channel 
gating. Their results indicated that the interaction of the 
Phe508 side chain did play a role in channel gating and is 
required to keep the channel open (Cui, et al., 2006). 
This is the first direct evidence that a specific 
interaction of the Phe508 side chain plays a role in 
determining residency time in the closed state. Although the 
side chain is not essential for CFTR folding, it is important in 
ion channel function.  
 
Impact of F508 Mutation in NBD1 of CFTR on Domain 
Folding and Structure 
It has been proposed by many that the primary effect of the 
F508 mutation is to cause misfolding of the NBD1, which 
leads to the degradation of CFTR. Through structural and 
biophysical studies on human NBD1 domains, Lewis, et al. 
(2005) reported that they had failed to demonstrate 
significant changes of in vitro stability or folding kinetics in 
the presence or absence of F508 mutation. This raises the 
possibility that instead of causing the folding of NBD1, the 
primary effect of F508 is a disruption of proper interdomain 
interactions at the Phe508 site in CFTR (Lewis, et al., 2005). 
Lewis, et al. (2005) examined the crystal 
structures of the Phe508 region in mNBD1 (mouse NBD1, 
gold), hNBD1-7a- F508 (human NBD1, 7 base mutations, 
deletion of Phe508, cyan), and hNBD1-2b- F508A (human 
NBD1, 2 base mutations, no yield of F508, blue).  The 
three models were super positioned to each other and 
Lewis, et al. (2005) found that the F508 hNBD1 shows 
minimal conformational changes compared to mNBD1. 
 Looking at the worm diagrams of hNBD1-7a- 
F508 and hNBD1-2b- F508A Lewis, et al. (2005) were able 
to compare the structures of hNBD1 and mNBD1. They 
observed a difference between the conformations of the two 
hNBD1. The structure of hNBD1-7a- F508 indicated a 
deletion of Phe508 through the shortening of a loop present 
in hNBD1-2b- F508A. 
 Additionally, through surface topography, Lewis, et 
al. (2005) examined the worm diagrams of hNBD1-7a- 
F508 and hNBD1-2b- F508A and found them to be 
dramatically different. The surface topography of hNBD1-7a- 
F508 is altered at the site of the mutation, representing the 
presumed region of binding to the MSD1 of CFTR. When 
Phe508 is deleted, Val-510 (a side chain) is removeed from 
its normal position (Lewis, et al., 2005). 
 Thus, the domains of hNDB1 with and without the 
F508 mutation cause slight conformational changes. 
Although there are no significant differences in the folding 
properties of the two version of hNBD1, the slight structural 
change of hNBD1-7a- F508 suggests that interdomain 
interactions are likely to be considerably altered by the 
F508 mutation. These results demonstrate new insights 
into the molecular pathology of the predominance of the 
class II mutation, which may be of particular significance to 
efforts in discovery of treatment.  
 
G551D: A Class III Mutation 
 
A class III mutation affects CFTR function after the protein 
leaves the ER and is inserted in the plasma membrane. 
However, once it reaches the membrane, the chloride 
channel is defectively regulated.  In the past few years, 
researchers have been focusing on the different ways the 
most common mutations act in a cystic fibrosis cell.  G551D 
is the most common class III mutation and the third most 
common overall (Welsh, 2001); therefore, it is a good 
candidate for study.  G551D is a missense mutation, which 
results in an exchange of asparagine for glycine at the 551 
codon (McMorran, et al., 2001).  This mutation occurs in 2-
5% of CF patients.  G551D is located on the apical 
membrane; however, it binds nucleotides less frequently and 
has reduced NBD1 ATPase activity (Derand, 2002).  
Therefore, the regulation of the chloride channel is defective. 
 The G551D mutation was originally suspected to 
be located at or near the ATP binding domain.  However, 
Howell, et al. (2000) found that the binding site was actually 
not near the binding domain.  They realized that the 
substitution of the two amino acids caused the helix to 
loosen, therefore changing the shape of active ATP binding 
site (Howell, et al. 2000). 
G551D causes a defect in the immunological 
response to inflammatory stimuli.  McMorran, et al. (2001) 
infected mice with the G551D missense mutation using 
Pseudomonas aeruginosa. This is a bacterium that causes a 
lung infection to which CF patients are extremely 
susceptible.  The research showed the decreased 
immunological response by comparing body weight, number 
of bacteria in the lungs, and the amount of pro-inflammatory 
mediators (TNF-, KC and MIP-2) between G551D CF mice 
and mice with WT CFTR.  The CF mice showed twice as 
much body weight decrease and a greatly increased amount 
of bacteria when compared to the WT mice.  The CF mice 
also had a greater pro-inflammatory response with the TNF-
, showing a hyper-response to the bacteria.  The amount of 
TNF- decreased significantly after 48 hours, showing that 
there might be a feedback loop in which the diminished 
response causes further infection (McMorran, et al., 2001). 
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It was found that different mutations of CF would 
possibly require different types of treatment.  The G551D 
mutation responded differently to three different agents that 
strongly influence chloride channels compared to the 
response of another CFTR mutation, G1349D,.  The three 
agents used were phloxine B, pyrophosphate, and 2’-deoxy 
ATP.  The phloxine B and 2’-deoxy ATP had an effect on the 
G551D patients, whereas only the 2’-deoxy ATP had an 
effect on the G1349D patients.  The hypothesis given for 2’-
deoxy ATP working on both was that the binding sites for 
ATP are impeded by both of these mutations.  2’-deoxy ATP 
was able to act as normal ATP and help both mutations 
function properly.  The phloxine B increased the amount of 
chloride exiting the cell in the patients with the G551D 
mutation and in the patients with the G1349D mutation; 
however, it was not enough to save the cell in the latter (Cai, 
et al., 2006). 
Another form of treatment for the G551D mutation 
would be the addition of genistein, a molecule that improves 
chloride channel activity by increasing the amount of time 
the channel is open (Suaud, et al., 2002).  In WT CFTR 
cells, the normal chloride channel activity inhibits the 
epithelial Na
+
 channel, ENaC.  However, when the chloride 
channel activity is low, ENaC works to stimulate it.  In 
G551D CFTR cells, ENaC and CFTR do not interact 
normally.  Genistein was able to restore normal interactions 
between the two channels (Suaud, et al., 2002).    
 
Molecular Chaperones and Their Therapeutic Potentials 
 
In most cases, CF is caused by the mutation F508 in the 
CFTR gene.  The mutated protein is synthesized, but it is 
incapable of being sent to the plasma membrane through ER 
export due to misfolding.  In this process, many molecular 
chaperones and co-chaperones are involved through either 
aiding the protein’s entrance into the secretory pathway or 
targeting the protein for degradation.  Such chaperones 
include Hdj-2/Hsc70, Hsp90, and HspBP1.  Depending on 
their functions, different chaperones play distinct roles in 
different stages of CFTR folding.  Regulation of chaperone 
expression can be of great therapeutic value because once 
F508 is sent to the plasma membrane it will be at least 
partially functional (Pasyk and Foskett, 1995).  
 
Hdj-2/Hsc70 Chaperone Pair Facilitates CFTR Biogenesis 
CFTR consists of TMD 1 and 2, NBD 1 and 2, and an R 
domain.  The F508 mutation was found to be localized in 
NBD1 and causes CFTR to misfold (Lewis, et al., 2005).  
Thus chaperones that specifically help NBD1 to fold properly 
are of vital importance to the correct folding of CFTR.  
Human DnaJ2 (Hdj-2) is a co-chaperone of heat shock 
cognate 70 (Hsc70) (Meacham, et al., 1999).  Both have 
been isolated in complexes with CFTR and F508 CFTR.  In 
fact, the complexes that the chaperones formed with F508 
CFTR were ~2 fold more abundant than those with CFTR.  
These data indicate that not only do the chaperones interact 
with the protein, they also interact more with F508 than 
CFTR.   
To locate where the Hdj-2/Hsc70 chaperone pair 
works, the ability of these chaperones to form complexes 
with CFTR fragments was investigated.  It was found that 
with the expression of NBD1, there was an increase in the 
binding abilities of Hdj-2 and Hsc70.  When other domains 
were expressed, there was a decrease in their binding 
abilities.  To further analyze how the Hdj-2/Hsc70 complex 
interacts with NBD1, studies were done to find out whether 
its aggregation can be prevented.  The results show that 
Hdj-2/Hsc70 could suppress >85% of NBD1 aggregation.  
These data demonstrate that the Hdj-2/Hsc70 chaperone 
pair facilitates the early steps of CFTR folding, specifically  of  
 
 
Figure 2. This figure depicts how HspBP1 and BAG-1 compete with 
binding to Hsc70 and CHIP to either inhibit or stimulate the 
degradation of CFTR.  
 
the NBD1 region.  A theory for how CFTR folding is carried 
out was then proposed.  The first step is the insertion and 
orientation of the TMD1 into the ER membrane.  Then NBD1 
is synthesized and bound by Hdj-2 and Hsc70.  In the time 
before the R domain is synthesized, Hdj-2 and Hsc70 
stabilize NBD1 or promote its folding.  When the R domain 
and MSD2 are folded, Hdj-2 is released.  NBD2 is the last to 
be synthesized and CFTR is then in its final mature form and 
ready to be sent to the plasma membrane.  Thus, regulating 
the levels of Hdj-2/Hsc70 may help NBD1 folding and, in 
turn, facilitate the folding of CFTR.  Current investigation of 
the Hdj-2/Hsc70 chaperone pair includes investigating 
whether it is a common component of the machinery that 
helps membrane protein biogenesis (Meacham, et al., 1999). 
 
Hsp90 Contributes to CFTR Maturation 
Hsp90 is an abundant chaperone in cells that plays an 
important role in preventing protein aggregation and helping 
proteins fold or degrade (Smith, et al., 1995).  Thus, studies 
were done to find out whether Hsp90 can facilitate CFTR 
and F508 CFTR folding.  Hsp90 was found to bind to both 
CFTR and F508 CFTR (Loo, et al., 1998).  Ansamysin is a 
drug that inhibits that association between Hsp90 and its 
substrate.  Then, whether ansamysin would also destroy the 
binding between Hsp90 and CFTR was investigated.  In fact, 
no CFTR was found to be associated with Hsp90, indicating 
that the CFTR-Hsp90 complex was immediately perturbed 
when the drug was used.  Once this was found, the effects 
of ansamysin on the synthesis of CFTR and F508 CFTR 
was studied.  Ansamysin inhibited the maturation of both 
forms of CFTR.  Connecting these results, it can be 
concluded that if the association between Hsp90 and CFTR 
is disrupted, the maturation of CFTR cannot be achieved.  
Another hypothesis was that the perturbation of the Hsp90 
and CFTR association would also accelerate the 
degradation of immature CFTR by proteasomes.  This was 
investigated by looking at the effects of ansamysin alone 
compared to the effects of ansamysin and a proteasome 
inhibitor, lactacystin, on the synthesis of CFTR.  As 
predicted, with just ansamysin there was a decrease in the 
amount of mature CFTR and lactacystin corrected its 
negative effects.   
Concluding the data above, disrupting the 
association between Hsp90 and CFTR will inhibit the 
maturation of the protein and accelerate its degradation by 
the proteasome.  Thus, regulation of Hsp90 can be used as 
therapy.  Partner proteins of Hsp90 (such as p23) are also 
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being investigated to see if they play a role in facilitating 
Hsp90 in its function (Loo, et al., 1998). 
 
HspBP1 Inhibits CFTR Degradation and Stimulates CFTR  
Maturation 
There are two pathways in which CFTR can be directed 
while trafficking through the ER depending on whether it is 
folded properly or misfolded.  When it is correctly folded, the 
CFTR protein will be sent to the plasma membrane and 
function normally.  When it is misfolded, it will be recognized 
by specific chaperones and targeted for degradation.  One of 
these chaperones is Hsc70 associated with CHIP (Connell, 
et al., 2001).  By binding to Hsc70, CHIP induces the 
ubiquitination of the target protein, thus targeting it for 
degradation by the proteasome (Meacham, et al., 2001).  
There are other co-chaperones that form complexes with 
Hsc70/CHIP, which either enhance or inhibit its degradation 
activity.  BAG-1 is a co-chaperone that promotes 
degradation when it binds to the complex.  HspBP1 is 
another important co-chaperone and studies were done to 
find out whether it regulates the function of the Hsc70/CHIP 
complex.  First of all, HspBP1 and CHIP were found to bind 
to Hsc70 at the same time but at different positions.  Thus 
they do not inhibit each other’s actions; instead they work in 
cooperation.  When bound to the Hsc70/CHIP complex, 
HspBP1 was found to inhibit the ubiquitin ligase activity of 
CHIP, thus slowing the rate of degradation of CFTR.  Thus, 
HspBP1 is another chaperone that, if it can be regulated, it 
will help the process of sending CFTR to the membrane 
(Meacham, et al., 2001).   
 
Innovative Treatment Possibilities 
 
Aside from common therapies such as lung transplantation, 
airway-clearing techniques, inhaled drugs, and antibiotics, 
recent research shows promise for other techniques 
addressing CF symptoms (CFF.org, 2007).  
 
Curcumin sends F508 CFTR to the plasma membrane 
Curcumin is a major component of the Indian curry spice 
turmeric, which can act as a low-affinity sarcoplasmic/ 
endoplasmic reticulum calcium pump inhibitor (Egan, et al., 
2004). It was recently found to have possible therapeutic 
effects on F508 CFTR. When BHK cell lines containing 
F508 CFTR were treated with curcumin, the surface 
density of the CFTR channels were found to significantly 
increase (Egan, et al., 2004).  Using an iodide efflux assay 
with cAMP activation of the chloride channels, Egan, et al. 
(2004) were able to demonstrate that through its increased 
density at the plasma membrane, F508 CFTR functions 
properly as chloride channels.  Therefore it corrects the CF 
phenotype. 
 Results from co-immunoprecipitation suggest that 
curcumin interacts with Calnexin, a co-chaperone of Hsp90, 
which is involved in CFTR folding. Calnexin failed to 
coprecipitate with CFTR when the cells were treated with 
curcumin, suggesting that the interaction was inhibited. 
Thus, calnexin is thought to play a role in retaining F508 
CFTR in the ER (Egan, et al., 2004).   
 
Oligonucleotide Insertion Corrects F508 CFTR  
Oligonucleotide insertion has also shown some promising 
therapeutic effects involving F508 CFTR cell lines 
(Zamecnik, et al., 2004). This method of treatment intercepts 
the transcribed mRNA of the F508 CFTR mutated gene, 
then corrects the deletion through insertion of nucleotide 
sequences that code for the missing phenylalanine. This 
corrected mRNA can then be translated into the WT CFTR 
protein, which is processed normally and transported to the 
plasma membrane. Zamecnik, et al. (2004) further show that 
the CFTR corrected by oligonucleotide insertion was 
functional at the plasma membrane by measuring the current 
after cAMP stimulation. Thus, oligonucleotide insertion 
prevents the development of the CF phenotype. While this 
treatment would not reverse the genotype of CF patients, it 
would be a preventative therapy.  
  
Cardiac Glycosides Suppress IL-8 Secretion 
Another fascinating advance in the realm of CF treatment is 
the use of cardiac glycosides, such as digitoxin, (Srivastava, 
et al., 2004).  Cardiac glycosides are drugs that are usually 
used in the treatment of congestive heart failure. They work 
by inhibiting the Na
+
/K
+
 pump, which leads to an increase in 
the Ca
2+
 level, aiding in contraction of the heart muscle. This 
improves cardiac output and reduces any swelling of the 
heart. One of the major characteristics of CF is extensive 
lung inflammation, which is believed to be caused by 
hypersecretion of the pro-inflammatory protein IL-8. The 
ability of cardiac glycoside’s to reduce swelling led 
researchers to investigate their effects on F508 CFTR cells.  
 All of the cardiac glycosides tested inhibited the 
secretion of IL-8, with digitoxin being the most efficient. 
Digitoxin blocks the phosphorylation of IKB, an inhibitor of 
NF-B activation, which stops the signaling pathway for 
hypersecretion of IL-8.  
 When treatment with digitoxin was compared to 
gene therapy, an interesting result emerged. Gene therapy 
significantly changes 58 genes, and 36 of those were 
equivalently and proportionately changed by treatment with 
digitoxin (Srivastava, et al., 2004). This suggests that 
digitoxin mimics the genomic effects of gene therapy on 
F508 CFTR. 
 
Conclusion 
 
Cystic fibrosis is an autosomal recessive disease caused by 
mutations in the chloride channel, CFTR. The F508 
mutation of the CFTR gene, which was found to influence 
kinase-binding sites, accounts
 
for the vast majority of CF. 
Concentrating on defining F508 and its functions will lead 
to better understanding of this fatal defect and its molecular 
consequences.  Another mutation, G551D, causes a shape 
change in NBD1. This makes it impossible for ATP to bind 
and activate the open-state of CFTR.  Molecular chaperones 
can interact with CFTR in its folding and transport process in 
such a way that CFTR and its mutated form can both be sent 
to the plasma membrane and function normally.  Some 
examples include the Hdj-2/Hsc70 pair which can facilitate 
the early biogenesis of CFTR, Hsp90 which can aid in CFTR 
maturation, and HspBP1 which can inhibit degradation and 
accelerate maturation of CFTR.  Thus chaperones have 
significant potential in the treatment of CF.  Aside from the 
common treatment techniques, curcumin and oligonucleotide 
insertion have been shown to successfully transport F508 
CFTR to the plasma membrane, correcting the CF 
phenotype. Digitoxin inhibits hypersecretion of IL-8, therefore 
preventing the inflammatory symptoms of CF.  In order to 
assess the effectiveness of the aforementioned treatments, 
future clinical trials are needed. 
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